Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 548pembrolizumab 382Radiotherapy 363Bevacizumab 359Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × sotigalimab × Clear all
NCT02706353 2025-11-21

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
34 enrolled 18 charts
Dermatologic

Melanoma

NCT03502330 2024-07-03

APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

Yale University

Phase 1 Completed
42 enrolled 17 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡